ConductScience.org, home

Comparison · NCT03740997-sae

Body Weight Group <=40 kg: OPTISON vs Body Weight Group >40 kg: OPTISON: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Body Weight Group <=40 kg: OPTISON vs Body Weight Group >40 kg: OPTISON: serious adverse events. Trial comparisons, record NCT03740997-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03740997-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.324wilson
Risk in group 2000.117wilson
Risk difference, group 1 minus group 20-0.1170.324newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Body Weight Group <=40 kg: OPTISON
Participants with body weight \>=20 to \<=28 kg received OPTISON 0.1 mL (dose level 1) or 0.2 mL (dose level 2); and participants with body weight \>28 to \<=40 kg received OPTISON 0.2 mL (dose level 1) or 0.3 mL (dose level 2) IV injection, 10 minutes apart on Day 1. The maximum allowed cumulative dose for body weight \>=20 to \<=28 kg and \>28 to \<=40 kg was 1.0 mL and 1.5 mL per dose level, respectively.~All subjects were imaged without contrast then with dose level 1 and then dose level 2. So it is impossible to separate the AE for each intervention.
08EG000
Group 2Body Weight Group >40 kg: OPTISON
Participants with body weight \>40 kg received OPTISON 0.2 (dose level 1) or 0.4 mL (dose level 2) IV injection, 10 minutes apart on Day 1. The maximum allowed cumulative dose was 1.8 mL per dose level.~All subjects were imaged without contrast then with dose level 1 and then dose level 2. So it is impossible to separate the AE for each intervention.
029EG001

Harm

What it counts
Total, serious adverse events
Time frame
0- 72 hours

Source ClinicalTrials.gov

Trial

Title
Study to Determine Safety and Dosage of OPTISON in Pediatric Participants
NCT number
NCT03740997
Phases
PHASE4
Conditions
Transthoracic Echocardiography, Suspected or Known Structural or Functional Cardiac Abnormality
Interventions
Optison
Lead sponsor
GE Healthcare
Results first posted
2024-05-17

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03740997-sae